Provided by Tiger Trade Technology Pte. Ltd.

Hillhouse Capital Holdings

4,902.55
+72.321.50%
Number of Gainers:43
Number of Losers:20
Number of Flat:2
PE:- -
High:4,912.34
Open:4,848.84
Low:4,830.37
Close:4,830.23
Volume:306.23M
Turnover:31.41B
Market Cap:8.75T
Float Cap:8.30T

Loading ...

Software Stocks Rise Against the Broad Tech Selloff

Tiger Newspress
·
Sep 14

UBS Remains a Hold on Otis Worldwide (OTIS)

TIPRANKS
·
Sep 14

Taiwan Semiconductor Manufacturing Co Ltd Stock (TSM) Opened Down by 3.26% on Sep 14: What Signal Does It Send?

TradingKey
·
Sep 14

Musk’s X Corp and Xai Resolve Antitrust Lawsuit Against Apple - Court Filing

THOMSON REUTERS
·
Sep 14

Apple Buy Rating Reaffirmed as Analyst Sees Strong iPhone 18 Trends, AI Upside and Keeps Price Target Unchanged at $370

TIPRANKS
·
Sep 14

Analysts Conflicted on These Technology Names: Apple (AAPL) and Oracle (ORCL)

TIPRANKS
·
Sep 14

UL Solutions launches new certification program for vehicle-to-grid tech

TIPRANKS
·
Sep 14

Legend Biotech Updates and Expands Cell Therapy Clinical Pipeline

TIPRANKS
·
Sep 14

MINISO Steps Up Hong Kong Share Buybacks in September 2026

TIPRANKS
·
Sep 14

Salesforce Announces $27 Million in New Education Grants, Deepening Support for Public Schools and Educators

THOMSON REUTERS
·
Sep 14

【US Pre-Market】US Stock Futures Fall as AI Giants Call to Slow Model Development; AI Supply Chain Tumbles, Led by Memory and Optical Sectors

TradingKey
·
Sep 14

Enphase Energy to Showcase IQ Solid-State Transformer at AI Infra Summit 2026

GlobeNewswire
·
Sep 14

Immunocore Completes Enrollment in Phase 3 Melanoma Trial

TIPRANKS
·
Sep 14

Top Premarket Decliners

MT Newswires Live
·
Sep 14

The Tech Selloff is About More than AI Slowdown Fears

Dow Jones
·
Sep 14

Cytokinetics Announces Call for Proposals for Ninth Annual Communications Grant Program

THOMSON REUTERS
·
Sep 14

Immunocore achieves target patient enrollment in TEBE-AM clinical trial

TIPRANKS
·
Sep 14

Nomura Adjusts GDS Holdings Price Target to $45.70 From $48.40, Maintains Buy Rating

MT Newswires Live
·
Sep 14

Immunocore - Achieves Target Enrollment in Tebe-am Trial with Kimmtrak in Advanced Melanoma

THOMSON REUTERS
·
Sep 14

Immunocore - Topline Overall Survival Data from Tebe-am Trial Expected by End of 2026

THOMSON REUTERS
·
Sep 14